论文部分内容阅读
[目的]探讨伊托必利联合黛力新治疗功能性消化不良(FD)的临床有效性和安全性。[方法]纳入216例FD患者,随着分为试验组108例和对照组108例,前者采用伊托必利联合黛力新治疗,后者采用伊托必利治疗,治疗4周后,采用χ2检验比较消化道症状和抑郁症状的疗效。[结果]试验组的总有效率为92.59%,显著高于对照组的82.41%(χ2=4.738,P=0.030);治疗后试验组焦虑抑郁症状严重程度的分布有显著变化(χ2=20.270,P<0.001),而对照组无明显改变(χ2=5.024,P=0.170),试验组的症状严重程度分布与对照组比较,差异有统计学意义(χ2=9.428,P=0.024);2组不良反应发生率比较差异无统计学意义(P>0.05)。[结论]伊托必利联合黛力新对FD的消化道症状和抑郁症状安全有效,值得临床推广应用。
[Objective] To investigate the clinical efficacy and safety of Itopride combined with Deanxit in the treatment of functional dyspepsia (FD). [Methods] A total of 216 patients with FD were enrolled and divided into experimental group (n = 108) and control group (n = 108). The former was treated with Itopride combined with Deanxit and the latter with Itopride. After 4 weeks of treatment, χ2 test compared the efficacy of gastrointestinal symptoms and depressive symptoms. [Results] The total effective rate of the experimental group was 92.59%, which was significantly higher than that of the control group (χ2 = 4.738, P = 0.030). The severity of anxiety and depression in the experimental group changed significantly after treatment (χ2 = 20.270, (Χ2 = 5.024, P = 0.170). There was a significant difference in the severity of symptoms between the control group and the control group (χ2 = 9.428, P = 0.024). There was no significant difference between the two groups The incidence of adverse reactions was no significant difference (P> 0.05). [Conclusion] Itopride combined with Deanxit is safe and effective for gastrointestinal symptoms and depressive symptoms of FD, which is worthy of clinical application.